| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. Built for biotech. |
Today's Rundown Conatus wields ax as Novartis-partnered NASH drug fails again FDA kicks back Acer's rare disease drug, demands new test—shares in freefall Verona hires ex-GSK researchers for late-phase push in COPD [Sponsored] Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx After being snapped up by Alexion, Syntimmune's CEO joins MorphoSys Almirall hands over $50M for European rights to Dermira's Dupixent challenger Minerva's sleep drug bests Ambien, placebo in dose-finding study AbbVie bails out struggling Allergan with $63B deal Featured Story | | | Tuesday, June 25, 2019 A phase 2b trial of Conatus Pharmaceuticals’ emricasan in NASH has missed its primary endpoint. The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives. |
|
|
Top Stories Tuesday, June 25, 2019 Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol). Tuesday, June 25, 2019 Verona Pharma has named long-time GlaxoSmithKline employee Nina Church as executive director of global clinical development. The hire is part of efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease. Monday, June 24, 2019 Frontage is Growing to Meet All Your Needs! Tuesday, June 25, 2019 New York rare disease biotech Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion Pharmaceuticals in 2018 for up to $1.2 billion. Tuesday, June 25, 2019 Almirall paid Dermira $30 million for the exclusive right to license the latter’s atopic dermatitis treatment in Europe. Now, the Spanish biotech is pulling the trigger on that option to take over a program it reckons could rake in €450 million. Monday, June 24, 2019 Minerva Neurosciences’ seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s insomnia drug Ambien in a phase 2b study. Tuesday, June 25, 2019 Allergan investors have been pushing for action from its management amid struggles, and AbbVie has been hunting for new revenue streams. Now, the companies are set to combine. Resources Sponsored by: Titian Software This Essential Guide to Managing Laboratory Samples is a three-part piece exploring common problems experienced in the management of samples and how, for any scale of operation, significant efficiency and accuracy benefits can be gained using dedicated sample management software. Sponsored by: Elemental Machines How can the Internet of Things (IoT) enable you to meet GxP? Sponsored by: Veradigm Patients living with diabetes deserve better – Real-World Evidence for effecting/realizing change in the management of type 2 diabetes and cardiovascular/renal comorbidities. Sponsored by: OCT Clinical Trials | June 20, 2019 | 2pm EDT / 11am PDT Fast and cost-efficient patient-enrollment,100% success strategy for obtaining a CTA, unified market authorization across the EEU countries. Find out the key compelling reasons to conduct studies in Russia. Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 